160 related articles for article (PubMed ID: 36744544)
1. Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group.
Speight B; Hanson H; Turnbull C; Hardy S; Drummond J; Khorashad J; Wragg C; Page P; Parkin NW; Rio-Machin A; Fitzgibbon J; Kulasekararaj AG; Hamblin A; Talley P; McVeigh TP; Snape K;
Br J Haematol; 2023 Apr; 201(1):25-34. PubMed ID: 36744544
[TBL] [Abstract][Full Text] [Related]
2. Management of patients with germline predisposition to haematological malignancies considered for allogeneic blood and marrow transplantation: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar, NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group and the British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCT).
Clark A; Thomas S; Hamblin A; Talley P; Kulasekararaj A; Grinfeld J; Speight B; Snape K; McVeigh TP; Snowden JA
Br J Haematol; 2023 Apr; 201(1):35-44. PubMed ID: 36786081
[TBL] [Abstract][Full Text] [Related]
3. Co-design of patient information leaflets for germline predisposition to cancer: recommendations for clinical practice from the UK Cancer Genetics Group (UKCGG), Cancer Research UK (CRUK) funded CanGene-CanVar Programme and the Association of Genetic Nurse Counsellors (AGNC).
Kohut K; Speight B; Young J; Way R; Wiggins J; Monje-Garcia L; Eccles DM; Foster C; Turner L; Snape K; Hanson H; ;
J Med Genet; 2024 Jan; 61(2):142-149. PubMed ID: 38050080
[TBL] [Abstract][Full Text] [Related]
4. Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.
Tsoulaki O; Tischkowitz M; Antoniou AC; Musgrave H; Rea G; Gandhi A; Cox K; Irvine T; Holcombe S; Eccles D; Turnbull C; Cutress R; ; Archer S; Hanson H
Br J Cancer; 2024 Jun; ():. PubMed ID: 38834743
[TBL] [Abstract][Full Text] [Related]
5. Germline predisposition in myeloid neoplasms: Unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes.
Sahoo SS; Kozyra EJ; Wlodarski MW
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101197. PubMed ID: 33038986
[TBL] [Abstract][Full Text] [Related]
6. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
7. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies.
Drazer MW; Kadri S; Sukhanova M; Patil SA; West AH; Feurstein S; Calderon DA; Jones MF; Weipert CM; Daugherty CK; Ceballos-López AA; Raca G; Lingen MW; Li Z; Segal JP; Churpek JE; Godley LA
Blood Adv; 2018 Jan; 2(2):146-150. PubMed ID: 29365323
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.
Homan CC; Drazer MW; Yu K; Lawrence DM; Feng J; Arriola-Martinez L; Pozsgai MJ; McNeely KE; Ha T; Venugopal P; Arts P; King-Smith SL; Cheah J; Armstrong M; Wang P; Bödör C; Cantor AB; Cazzola M; Degelman E; DiNardo CD; Duployez N; Favier R; Fröhling S; Rio-Machin A; Klco JM; Krämer A; Kurokawa M; Lee J; Malcovati L; Morgan NV; Natsoulis G; Owen C; Patel KP; Preudhomme C; Raslova H; Rienhoff H; Ripperger T; Schulte R; Tawana K; Velloso E; Yan B; Kim E; Sood R; Hsu AP; Holland SM; Phillips K; Poplawski NK; Babic M; Wei AH; Forsyth C; Mar Fan H; Lewis ID; Cooney J; Susman R; Fox LC; Blombery P; Singhal D; Hiwase D; Phipson B; Schreiber AW; Hahn CN; Scott HS; Liu P; Godley LA; Brown AL;
Blood Adv; 2023 Oct; 7(20):6092-6107. PubMed ID: 37406166
[TBL] [Abstract][Full Text] [Related]
9. Implementation of the updated NICE haematological cancers (NG47) improving outcomes guidelines across Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) in England: a UK NEQAS LI survey.
Cartwright A; Snowden JA; Whitehouse H; Scott S; Whitby L
J Clin Pathol; 2023 Sep; 76(9):618-623. PubMed ID: 35508367
[TBL] [Abstract][Full Text] [Related]
10. Incidental detection of germline variants of potential clinical significance by massively parallel sequencing in haematological malignancies.
Yannakou CK; Jones K; Ryland GL; Thompson ER; Reid G; McBean M; Trainer A; Westerman D; Blombery P
J Clin Pathol; 2018 Jan; 71(1):84-87. PubMed ID: 28801348
[TBL] [Abstract][Full Text] [Related]
11. Pedigree investigation, clinical characteristics, and prognosis analysis of haematological disease patients with germline TET2 mutation.
Wu X; Deng J; Zhang N; Liu X; Zheng X; Yan T; Ye W; Gong Y
BMC Cancer; 2022 Mar; 22(1):262. PubMed ID: 35279121
[TBL] [Abstract][Full Text] [Related]
12. Identifying patients with genetic predisposition to acute myeloid leukemia.
Obrochta E; Godley LA
Best Pract Res Clin Haematol; 2018 Dec; 31(4):373-378. PubMed ID: 30466750
[TBL] [Abstract][Full Text] [Related]
13. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study.
Moriyama T; Metzger ML; Wu G; Nishii R; Qian M; Devidas M; Yang W; Cheng C; Cao X; Quinn E; Raimondi S; Gastier-Foster JM; Raetz E; Larsen E; Martin PL; Bowman WP; Winick N; Komada Y; Wang S; Edmonson M; Xu H; Mardis E; Fulton R; Pui CH; Mullighan C; Evans WE; Zhang J; Hunger SP; Relling MV; Nichols KE; Loh ML; Yang JJ
Lancet Oncol; 2015 Dec; 16(16):1659-66. PubMed ID: 26522332
[TBL] [Abstract][Full Text] [Related]
14. Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.
Király AP; Kállay K; Gángó A; Kellner Á; Egyed M; Szőke A; Kiss R; Vályi-Nagy I; Csomor J; Matolcsy A; Bödör C
Pathol Oncol Res; 2018 Jan; 24(1):83-88. PubMed ID: 28357685
[TBL] [Abstract][Full Text] [Related]
15. Review of guidelines for the identification and clinical care of patients with genetic predisposition for hematological malignancies.
Schlegelberger B; Mecucci C; Wlodarski M
Fam Cancer; 2021 Oct; 20(4):295-303. PubMed ID: 34057692
[TBL] [Abstract][Full Text] [Related]
16. Approach Toward Germline Predisposition Syndromes in Patients with Hematologic Malignancies.
Atluri H; Gerstein YS; DiNardo CD
Curr Hematol Malig Rep; 2022 Dec; 17(6):275-285. PubMed ID: 36279069
[TBL] [Abstract][Full Text] [Related]
17. Hereditary Predisposition to Hematopoietic Neoplasms: When Bloodline Matters for Blood Cancers.
Mangaonkar AA; Patnaik MM
Mayo Clin Proc; 2020 Jul; 95(7):1482-1498. PubMed ID: 32571604
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).
DiNardo CD; Bannon SA; Routbort M; Franklin A; Mork M; Armanios M; Mace EM; Orange JS; Jeff-Eke M; Churpek JE; Takahashi K; Jorgensen JL; Garcia-Manero G; Kornblau S; Bertuch A; Cheung H; Bhalla K; Futreal A; Godley LA; Patel KP
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):417-428.e2. PubMed ID: 27210295
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes.
Martin ES; Ferrer A; Mangaonkar AA; Khan SP; Kohorst MA; Joshi AY; Hogan WJ; Olteanu H; Moyer AM; Al-Kali A; Tefferi A; Chen D; Wudhikarn K; Go R; Viswanatha D; He R; Ketterling R; Nguyen PL; Oliveira JL; Gangat N; Lasho T; Patnaik MM
Am J Hematol; 2021 Nov; 96(11):1450-1460. PubMed ID: 34390506
[TBL] [Abstract][Full Text] [Related]
20. Inherited predisposition to haematopoietic malignancies: overcoming barriers and exploring opportunities.
Trottier AM; Godley LA
Br J Haematol; 2021 Aug; 194(4):663-676. PubMed ID: 33615436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
